17 completed. 17 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 17 |
| Phase 2 | 6 | Completed 6 |
Follow Stroke, Acute: new trials by email Literature Review of Stroke, Acute trials Research Report on Stroke, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2). Intraarterial alteplase - Stroke, Acute Ischemic, Stroke, Acute | Phase 3 | Completed | Hospital Clinic of Barcelona | 440 | 2023-11-18 | 2026-09-18 |
| PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE) Propranolol Hydrochloride, control group - Stroke, Vascular Accident | Phase 2 / Phase 3 | Completed | Beijing Tiantan Hospital | 168 | 2023-02-21 | 2025-07-14 |
| Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study Glenzocimab, Placebo - Stroke, Acute, Stroke, Ischemic | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 108 | 2023-01-03 | 2026-07-08 |
| Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke rhTNK-tPA, Endovascular treatment - Stroke, Acute, Stroke, Ischemic | Phase 2 / Phase 3 | Completed | Xinqiao Hospital of Chongqing | 550 | 2022-05-09 | 2025-04-03 |
| Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke Clevidipine - Stroke, Acute, Blood Pressure | Phase 3 | Completed | ProMedica Health System | 80 | 2021-10-30 | 2025-01-07 |
| Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis Placebo, Nerinetide - Stroke, Acute | Phase 3 | Completed | NoNO Inc. | 850 | 2020-12-06 | 2025-06-22 |
| Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial urapidil - Stroke, Acute, Cerebrovascular Disorders | Phase 3 | Completed | The George Institute for Global Health, China | 2425 | 2020-03-20 | 2025-03-26 |
| Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke Tenecteplase, Alteplase - Stroke, Acute, Thromboses, Intracranial | Phase 3 | Completed | University of Calgary | 1600 | 2019-12-10 | 2023-05-12 |
| Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment - Cerebral Ischemia, Cerebral Infarction | Phase 3 | Completed | Pharmazz, Inc. | 158 | 2019-11-10 | 2023-10-18 |
| Intraarterial Alteplase Versus Placebo After Mechanical Thrombectomy Intraarterial alteplase, Placebo - Stroke, Acute | Phase 2 / Phase 3 | Completed | Hospital Clinic of Barcelona | 121 | 2018-12-05 | 2022-05-20 |
| Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements HLCM051, Placebo - Stroke, Acute | Phase 2 / Phase 3 | Completed | Healios K.K. | 206 | 2017-11-15 | 2024-01-17 |
| Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke Nerinetide (NA-1), 2.6 mg/kg, Placebo - Stroke, Acute | Phase 3 | Completed | NoNO Inc. | 1105 | 2017-03-01 | 2022-10-10 |
| A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion Tenecteplase, Antiplatelet treatment - Stroke, Acute | Phase 3 | Completed | University of Calgary | 1274 | 2015-04-01 | 2025-01-31 |
| Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2) Desmoteplase, Placebo - Stroke, Acute | Phase 3 | Completed | Forest Laboratories | 193 | 2005-04-01 | 2012-03-20 |
| Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke NXY-059 - Cerebral Stroke, Stroke, Acute | Phase 3 | Completed | AstraZeneca | 3200 | 2003-05-01 | 2010-11-15 |
| A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke EGb761, Placebo, Acetylsalicylic acid - Stroke, Acute, Neurological Impairment | Phase 3 | Completed | Ipsen | 204 | 2003-02-01 | 2019-01-08 |
| Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke recombinant human erythropoietin alfa, 0.9% NaCl - Infarction, Middle Cerebral Artery, Middle Cerebral Artery Stroke | Phase 2 / Phase 3 | Completed | Max-Planck-Institute of Experimental Medicine | 522 | 2003-01-01 | 2008-10-22 |
Stroke (17) · Ischemic Stroke (5) · Ischemia (2) · Brain Ischemia (1) · Cataplexy (1) · Cerebral Hemorrhage (1) · Cerebral Infarction (1) · Cerebrovascular Disorders (1) · Hemorrhage (1) · Hemorrhagic Stroke (1) · Hypertension (1) · Hypoxia (1) · Infarction, Middle Cerebral Artery (1) · Infections (1) · Intracranial Hemorrhages (1)
Brain Diseases (17) · Cardiovascular Diseases (17) · Central Nervous System Diseases (17) · Nervous System Diseases (17) · Vascular Diseases (17) · Cerebrovascular Disorders (16) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Brain Infarction (2) · Brain Ischemia (2) · Infarction (2) · Necrosis (2) · Signs and Symptoms (2) · Cerebral Arterial Diseases (1) · Cerebral Infarction (1)
Tenecteplase (3) · TNK-tissue plasminogen activator (2) · Aspirin (1) · Clopidogrel (1) · Control Groups (1) · Ginkgo biloba extract (1) · Propranolol (1) · Saline Solution (1) · Tissue Plasminogen Activator (1) · clevidipine (1) · disufenton sodium (1) · glenzocimab (1) · salivary plasminogen activator alpha 1, Desmodus rotundus (1) · sovateltide (1) · urapidil (1)
Hospital Clinic of Barcelona (2) · NoNO Inc. (2) · University of Calgary (2) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Beijing Tiantan Hospital (1) · Forest Laboratories (1) · Healios K.K. (1) · Ipsen (1) · Max-Planck-Institute of Experimental Medicine (1) · Pharmazz, Inc. (1) · ProMedica Health System (1) · The George Institute for Global Health, China (1) · Xinqiao Hospital of Chongqing (1)
Canada (6) · Australia (5) · Germany (5) · Spain (5) · United States (5) · China (4) · Austria (3) · United Kingdom (3) · Brazil (2) · Czechia (2) · Finland (2) · France (2) · Ireland (2) · Netherlands (2) · New Zealand (2)
Angel Chamorro, MD, PhD (2) · Pol Camps, MD (2) · Ana Morales, MD (1) · Anil Gulati, MD, PhD (1) · Anna Ramos, MD (1) · Bijoy K Menon, MD (1) · Craig Anderson (1) · Elisa Cuadrado, MD, PhD (1) · Gang Li (1) · Jeffrey L Saver, MD (1) · Jie Yang (1)
PMID 17687131, PMID 19097942, PMID 19834012, PMID 21852153, PMID 22474060, PMID 22738918, PMID 26387127, PMID 29134924, PMID 32087818, PMID 33428177, PMID 33464335, PMID 34872617, PMID 35143603, PMID 35779553, PMID 37082967, PMID 37165867, PMID 37800372, PMID 38124205, PMID 38165335, PMID 38174568, PMID 38227308, PMID 38272571, PMID 38275116, PMID 38676572, PMID 38752650, PMID 38768626, PMID 39236681, PMID 39379314, PMID 39435713, PMID 39542995, PMID 39648909, PMID 39955119, PMID 40122606, PMID 40123483, PMID 40396577, PMID 40541207, PMID 40677228, PMID 40866207, PMID 41143808, PMID 41815318, PMID 41855454, PMID 41980227, PMID 42096239, PMID 42261967, PMID 42318629, PMID 42488952, PMID 42623571, PMID 42734928, PMID 42848972
2023 (1)